Harmony Biosciences Holdings (HRMY) Gains from Investment Securities (2020)

Harmony Biosciences Holdings (HRMY) reported Gains from Investment Securities of $1.5 million for Q3 2020, up 248.17% sequentially from $438000.0 in Q2 2020.

Harmony Biosciences Holdings (HRMY) Gains from Investment Securities (2020) Analysis & Trends

Harmony Biosciences Holdings (HRMY) has 1 years of Gains from Investment Securities data on file, last reported at $1.5 million in Q3 2020.

  • For the quarter ending Q3 2020, Gains from Investment Securities changed N/A year-over-year to $1.5 million; the trailing twelve-month figure through Dec 2020 stood at $3.1 million (changed N/A YoY), and the FY2020 full-year result was $3.1 million, changed N/A from the prior year.
  • Gains from Investment Securities rose to $1.5 million in Q3 2020, from $438000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $1.5 million in Q3 2020 to a low of $438000.0 in Q2 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Harmony Biosciences Holdings 2.09 Bn 1.57 Bn 170.88 Mn

Historic Data

Download Data
DateValue
Sep 30, 2020 1.53 Mn
Sep 30, 2020 1.53 Mn
Jun 30, 2020 438,000.00
Jun 30, 2020 438,000.00
Mar 31, 2020 1.15 Mn
Mar 31, 2020 1.15 Mn